Posts Tagged ‘EPO’

Essentially biological processes for the production of plants and animals – EPO Enlarged Appeal Board decisions G2/07 and G1/08 – Essentially Biological Processes

Monday, December 13th, 2010

From Paul Cole

Opinions were handed down on 9th December in the above two cases concerning the scope of the exclusion of a.53(b) EPC 1973. That article is further defined in r.23b(5) EPC 1973, now r.26(5) EPC 2000 which specifies that such a process is essentially biological if it consists essentially of natural phenomena such as crossing or selection.

Case G2/87 arose from a referral of Technical Board of Appeal 3.3.04 in case T83/05 PLANT BIOSCIENCE/Broccoli and related to a method of producing broccoli (Brassica oleracea) with elevated levels of glucosinolates which are believed to be chemoprotective agents. The patent in issue claimed:

(more…)

Newsflash! EPO announces that it does not require search results from priority applications filed at the USPTO, JPO and UKIPO

Monday, December 13th, 2010

From Marks & Clerk – This is a correction to the post of December 10th.

Late yesterday – December 9, 2010 – a decision of the President of the European Patent Office (EPO) was posted on the EPO website confirming that the search results from a priority application filed at the US Patent Office (USPTO), Japan Patent Office (JPO) or UK Intellectual Property Office (UKIPO) do not need to be filed by the applicant at the EPO to satisfy the requirements of new Rule 141(1). The Rule 141(1) requirement is automatically satisfied due to arrangements between the EPO and USPTO/JPO/UKIPO.

Under Rule 141(1), from January 1, 2011, the EPO requires the search results of a priority application to be filed at the EPO on filing of the EP application or “without delay” once the results become available. The EPO hoped to arrange automatic transfer of these documents with some patent offices so that the applicant would not need to file the documents themselves. Such an arrangement has been reached with the USPTO, JPO and UKIPO. This arrangement is effective from January 1, 2011 and so will apply to all EP applications filed under new Rule 141(1).

It is important to note that this arrangement only exists with the USPTO, JPO and UKIPO. If an EP application claims priority from one or more applications filed with an office other than the USPTO, JPO or UKIPO, the applicant will still need to file the documents under Rule 141(1). Even if a US IDS has been filed at the USPTO, it will still be necessary to file search results at the EPO if at least one of the priority applications was filed at an office other than the USPTO, JPO or UKIPO.

For the EP applications where we still need to file the search results from the priority application, we need to file the search report or exam report issued by the patent office handling the priority application. We cannot file a letter explaining the content of the search/examination report, the EPO requires the actual document issued by the patent office.

In addition to requiring the search results of the priority application, the EPO (under Rule 141(3)) can ask for prior art taken into consideration in national or regional patent proceedings and concerning an invention to which the European patent application relates. The above agreement between the EPO and USPTO/JPO/UKIPO does not affect this additional request for information. However, if this additional information is required, the EPO will send a communication setting a time limit for response.

Obligation to submit search results to the EPO as of January 1, 2011

Friday, December 10th, 2010

Submitting search results of priority applications to the EPO will become obligatory as of January 1, 2011

The Implementing Regulations of the European Patent Convention will change as of January 1, 2011, which apply to European patent applications and international applications filed on or after that date. Thus, the new Rules do not apply to applications that have been filed prior to January 1, 2011.

According to amended Rule 141(1) EPC, an applicant claiming priority has to file a copy of the results of any search carried out by the Patent Office(s) with which the previous application(s) was/were filed. This copy has to be filed together with the European patent application or by entry into the European phase of a PCT application, or without delay after such results have been made available to the applicant. It has not yet been determined by the European Patent Office what exactly “without delay” means, but we recommend to provide the search results as soon as possible and within approximately two weeks after they have been made available to the applicant.
This obligation applies to search results in any form, i.e. as part of the search but also as part of an office action issued by the Patent Office with which the previous application was filed. This obligation persists as long as the European patent application is pending.

In view of the new rules, when providing us with instructions to file a European or international patent application with the EPO, claiming priority of an earlier application, please provide us with a copy of corresponding search results once these are available or with a statement that such search results are not available. If search results are available, please provide a copy of the corresponding official document issued by the Office of first filing. A translation of the search results or copies of the prior art cited therein is not required.

If no search results have been filed by the applicant, the EPO will invite according to new Rule 70b (1) the applicant to file, within a period of two months, the copy or a statement that the results of the search are not available. If the applicant fails to reply in due time to such invitation, the European patent application shall be deemed to be withdrawn.

Furthermore, please note that the EPO intends to set up an electronic environment for directly accessing these search results so that applicants claiming the priority of an application filed with an National Patent Office for which such an electronic system is in place will be exempted from the obligation to file a copy of the search results under Rule 141 (1) EPC. We expect that at least the countries USA, Japan and Korea will factually be exempted from this new provision. Unfortunately, respective decisions have not been published yet, but are expected to be published early next year.

Published with permission of

Eisenführ, Speiser & Partner – Patentanwälte Rechtsanwälte

www.eisenfuhr.com

Sustained release fluvastatin formulations – The UK Court of Appeal opinion in Activis UK Limited v Novartis AG [2010] EWCA Civ 82

Friday, February 19th, 2010

Post from Paul Cole

Sometimes a decision as to obviousness hinges on a single short point. In Graham v John Deere, the tipping point testimony was during cross-examination of the witness for the patentee, when he said that the allegedly inventive feature made no significant difference to the operation of the device. Once that evidence had been given, the outcome was inevitable, and references to Thomas Jefferson, though decorative, were mere dicta.

The controversy concerning the fluvastatin sustained release patent EP-B-0948320 (UK) falls into the same category. The patent was based on the premise that fluvastatin was so water-soluble that it was difficult to devise a sustained release formulation. Claim 1 as amended read:

A sustained release pharmaceutical composition comprising a water soluble salt of fluvastatin as active ingredient and being selected from the group consisting of matrix formulations, diffusion-controlled membrane coated formulations and combinations thereof, wherein the sustained release formulation releases the active ingredient over more than 3 hours.

The tipping point fact was that fluvastatin was not of such extreme water-solubility as to give rise to the difficulties alleged. After that had been established, the whole basis for patentability collapsed, as explained concisely by Jacob L.J. at the conclusion of his opinion, which also contains an implied warning that although it may be appropriate to rely on an earlier decision for a rule of law, the facts on which that earlier decision was reached are of little relevance:

Once the obstacle put forward in the Patent against being able to make a sustained formulation was shown to be illusory, then a sustained release formulation is obvious. You might get better efficacy or fewer side effects, but you would certainly get better compliance. In Pozzoli terms the only difference between the prior art and the claim is the idea of making a sustained release formulation. For that there was a technical motivation and no difficulty, real or apparent.

The PSA [problem-solution analysis] gives the same answer. What is the objective problem? Why that which the patentee himself stated – to produce a sustained release form of fluvastatin. Was the solution obvious? Yes, any of the standard methods for such formulations would clearly work: there is no reason why they would not.

There is no need and it would be wrong to re-formulate the problem as suggested by Mr. Meade. This is not a case where some prior art unknown to the patentee has turned up. Nor is it right to reformulate the problem as one of looking for better medical effects when that was not the problem as seen by the patentee or to reformulate the solution as having found such effects when the patentee has not promised any.

In the latter respect this case is quite unlike the case, relied upon by Mr. Meade, about a sustained release form of oxycodone recently considered by this court, Napp v Ratiopharm [2009] EWCA Civ 252, [2009] RPC 539. Oxycodone was, until the patent, known as a minor weak opiod generally administered, to the extent that it was administered at all, as a co-drug. The slow-release form transformed it, as the patent said, into a serious alternative to morphine – something that was wholly unexpected. Of course the invention was non-obvious.

The upshot is that I would uphold the decision of the Judge. Unlike him, however, I do not think the case was finely balanced. Once the basis of the Patent was proved illusory there was nothing left to save it.

Jacob L.J.’s opinion contains a lengthy discussion of the respective approaches to inventive step of the UK courts under Windsurfing/Pozzoli and of the EPO approach using PSA which may be valuable to students and has been praised as “a tutorial in the law of obviousness”. Readers may recall John Mortimer’s fictional barrister Rumpole, who knew little law, but was an expert on bloodstains and used his instinct for tipping point facts with devastating effect in the cases for which he was responsible. No magic touchstone is to be found either in the USA under Graham/KSR or in the UK under Windsurfing/Pozzoli because in both jurisdictions after certain mandatory preliminary enquiries the issue has to be decided on a case by case basis according to the evidence and without the distortion introduced by preconceptions in the mind of the decision-maker. The legal background is only a guide as to the appropriate enquiries to be made and what matters is the evidence as to the tipping point facts, of which in the present case there was only one.